Related Experiment Video
Updated: Apr 11, 2026
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy
Alejandro Baeza, María Vallet-Regí1
1Dpto. Química Inorgánica y Bioinorgánica. Universidad Complutense de Madrid. Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12. Madrid, Spain. valet@ucm.es.
Abstract:
The development of nanocarriers able transport and release therapeutic agents in a controlled manner has provided a promising alternative in the oncology field due to the lack of selectivity of the conventional treatments. The encapsulation of cytotoxic compounds within nanoparticles improves the pharmacokinetic profile of the trapped drugs and allows their selective accumulation into the tumoral tissue owing to the enhance permeation and retention effect (EPR. In addition, the selectivity of the nanocarrier can be enhanced attaching targeting agents on their surface able to be specifically recognized by cancer cells or by the tumor microenvironment. Among the different materials which can be employed, mesoporous silica nanoparticles (MCM-41 type constitutes a promising candidate due to their very interesting properties such as tuneable size, shape and porosity, high loading capacity, low toxicity, robustness and easiness fabrication and functionalization. This material presents a unique pore architecture which allows the synthesis of stimuliresponsive devices able to release the trapped drugs only in the presence of certain stimuli achieving a precise control on the drug dosage. This review presents some of the recent advances in the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on the stimuli-responsive systems able to release their load in response to external (light, magnetic field, temperature or ultrasounds or internal stimulus (enzymes, pH, redox, among others.
Insights
Mesoporous silica nanocarriers offer controlled drug delivery for cancer therapy, improving drug profiles and tumor targeting. Stimuli-responsive systems enhance precision by releasing therapeutics only when needed.
Area of Science:
- Nanotechnology
- Oncology
- Materials Science
Background:
- Conventional cancer treatments lack selectivity, leading to side effects.
- Nanocarriers improve drug pharmacokinetics and enable targeted tumor accumulation via the enhanced permeation and retention (EPR) effect.
- Surface functionalization of nanocarriers with targeting agents further enhances cancer cell specificity.
Purpose of the Study:
- To review recent advances in mesoporous silica nanocarriers for antitumoral therapy.
- To highlight the development of stimuli-responsive nanocarrier systems for controlled drug release.
- To discuss the potential of mesoporous silica nanoparticles (MCM-41 type) in oncology.
Main Methods:
- Utilizing mesoporous silica nanoparticles (MCM-41 type) for drug encapsulation.
- Designing stimuli-responsive nanocarriers for targeted drug release.
- Investigating external (light, magnetic field, temperature, ultrasound) and internal (enzymes, pH, redox) stimuli for drug release.
Main Results:
- Mesoporous silica nanoparticles offer tuneable properties, high loading capacity, low toxicity, and ease of fabrication.
- Stimuli-responsive systems enable precise control over drug dosage and release kinetics.
- Nanocarriers facilitate selective accumulation in tumoral tissue through the EPR effect.
Conclusions:
- Mesoporous silica nanocarriers, particularly stimuli-responsive systems, represent a promising platform for advanced cancer therapy.
- These nanocarriers offer improved drug delivery, enhanced targeting, and controlled release mechanisms.
- Further development in stimuli-responsive mesoporous silica nanocarriers holds significant potential for improving antitumoral treatment efficacy and patient outcomes.
